Loading...
XHEL
HRTIS
Market cap39mUSD
Oct 09, Last price  
1.34EUR
1D
0.00%
1Q
-23.43%
Jan 2017
-52.98%
IPO
-87.21%
Name

Herantis Pharma Oyj

Chart & performance

D1W1MN
XHEL:HRTIS chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
26.16%
Rev. gr., 5y
%
Revenues
0
0008001,95525,291000000000
Net income
-7m
L+34.04%
-1,446,259-394,000-781,000-8,356,000-16,045,000-4,424,508-2,165,000-4,180,000-8,005,000-9,153,000-23,576,000-9,324,000279,840-4,939,000-6,620,000
CFO
-6m
L-6.84%
0-224,2110-7,397,714-3,035,6610-3,732,246-5,958,209-8,560,700-9,933,607-8,943,912-4,636,006-6,545,000-6,097,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.

Key people

Timo Veromaa
Independent Chairman of the Board · since 2020
Antti Vuolanto
Chief Executive Officer · since 2022
Frans Wuite
Independent Vice Chairman of the Board · since 2022
Henri Huttunen
Chief Scientific Officer
Arnab Bhattacharjee
Senior Scientist
Sigrid Booms
Director of Clinical Development · since 2011
Rebecka Holmnas
Project Manager
Katarina Jaaskelainen
Project Manager
Jani Koskinen
Head of Quality and CMC Development · since 2019
Natalia Kulesskaya
Senior Scientist
Outi Lahdenpera
Chief Medical Officer
Satu Leikas
Project Manager
Jutta Poutanen
Chief Pharmaceutical Officer
Magnus Sjogren
Chief Medical Officer · since 2017
Paivi Vuorio
Project Manager
Hilde Furberg
Director · since 2021
Aki Prihti
Director · since 2014
James Phillips
Independent Director · since 2019
Mats Thoren
Independent Director · since 2020
URL
https://herantis.com/
IPO date
Jun 11, 2014
Employees
10
Domiciled in
FI
Incorporated in
FI
Headquarters & legal address
Bertel Jungin Aukio 1
02600 ESPOO
ESPOO FI-02600
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT